Immunoprecise Antibodies Ltd. announced that the EPO has issued a Decision to Grant for BioKey's patent application covering the company's HYFT® Technology used to organize and analyze biological sequence information. The HYFT Technology and methodology provide a novel way to efficiently tap into sequence information, allowing the extraction and use the relevant information therein to address the current problems in omics data integration and analysis. The HYFT Technology serves as the core of the BioStrand's LENSai Integrated TechnologyTMplatform which provides cutting-edge data solutions and antibody discovery.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1 USD | -5.66% | -10.71% | -41.52% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.52% | 27.89M | |
-0.28% | 90.59B | |
0.00% | 38.99B | |
-8.62% | 34.09B | |
+64.13% | 26.38B | |
-17.56% | 15.02B | |
-5.92% | 13.17B | |
-10.69% | 11.88B | |
-47.78% | 10.65B | |
+8.09% | 9.25B |
- Stock Market
- Equities
- IPA Stock
- News ImmunoPrecise Antibodies Ltd.
- ImmunoPrecise Antibodies Ltd. Announces European Patent Office to Grant Biokey’S Patent Application for Foundational HYFT® Technology